- Home
- ORGN vs TRVI Comparison
ORGN vs TRVI Comparison
Compare ORGN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- TRVI
- Stock Information
- Founded
- ORGN 2008
- TRVI 2011
- Country
- ORGN United States
- TRVI United States
- Employees
- ORGN N/A
- TRVI N/A
- Industry
- ORGN Major Chemicals
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- TRVI Health Care
- Exchange
- ORGN Nasdaq
- TRVI Nasdaq
- Market Cap
- ORGN 199.7M
- TRVI 211.4M
- IPO Year
- ORGN N/A
- TRVI 2019
- Fundamental
- Price
- ORGN $1.19
- TRVI $2.73
- Analyst Decision
- ORGN Strong Buy
- TRVI Strong Buy
- Analyst Count
- ORGN 1
- TRVI 8
- Target Price
- ORGN $3.00
- TRVI $9.13
- AVG Volume (30 Days)
- ORGN 1.4M
- TRVI 517.0K
- Earning Date
- ORGN 11-14-2024
- TRVI 11-06-2024
- Dividend Yield
- ORGN N/A
- TRVI N/A
- EPS Growth
- ORGN N/A
- TRVI N/A
- EPS
- ORGN N/A
- TRVI N/A
- Revenue
- ORGN $35,123,000.00
- TRVI N/A
- Revenue This Year
- ORGN $10.62
- TRVI N/A
- Revenue Next Year
- ORGN $175.99
- TRVI N/A
- P/E Ratio
- ORGN N/A
- TRVI N/A
- Revenue Growth
- ORGN 123.12
- TRVI N/A
- 52 Week Low
- ORGN $0.44
- TRVI $0.97
- 52 Week High
- ORGN $1.90
- TRVI $4.00
- Technical
- Relative Strength Index (RSI)
- ORGN 42.61
- TRVI 40.28
- Support Level
- ORGN $0.98
- TRVI $2.72
- Resistance Level
- ORGN $1.29
- TRVI $3.07
- Average True Range (ATR)
- ORGN 0.09
- TRVI 0.21
- MACD
- ORGN -0.01
- TRVI -0.02
- Stochastic Oscillator
- ORGN 52.14
- TRVI 11.01
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.